Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: A bridging study

Journal of Clinical Psychopharmacology

Volumn 16, Issue 6, 1996, Pages 454-458

  Sramek, John J ^a   Fresquet, Anna ^b   Marion Landais, Gaston ^c   Hourani, Jameel ^a   Jhee, Stanford S ^a   Martinez, Luis ^b   Jensen, Christof M ^c   Bolles, Kerry ^a   Carrington, Ann T ^c   Cutler, Neal R ^a,d  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b Laboratorios Dr Esteve SA   (Spain)

^c ABBOTT LABORATORIES   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LESOPITRON;

ADULT; ANXIETY NEUROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE; DRUG TOLERANCE; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES;

EID: 8044245942     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199612000-00009     Document Type: Article

References (31)

1. 1A receptors: in vitro and in vivo studies in the rat. Eur J Pharmacol 1994;255:185-96.
2. 1A receptor ligand E-4424 to inhibit aversive behavior in the mouse, rat and marmoset. J Pharmacol Exp Ther 1992;262:90-8.
3. Barnes NM, Cheng CHK, Costall B, Ge J, Kelly ME, Naylor RJ. Profiles of interaction of R(+)/S(-)-zacopride and anxiolytic agents in a mouse model. Eur J Pharmacol 1992;218:91-100.
4. 1A receptor ligand. Behav Pharmacol 1992;3[suppl 1]:23.
5. Cutler NR, Sramek JJ. Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study. Eur J Clin Pharmacol 1995;48:421-8.
6. Cutler NR, Sramek JJ. The target population in phase I clinical trials of cholinergic compounds in Alzheimer's disease: the role of the "bridging study." Alzheimer Dis Assoc Disord 1995;9:139-45.
7. Cutler NR, Sramek JJ, Veroff AE. Alzheimer's disease: optimizing drug development strategies. Chichester, England: John Wiley & Sons, 1994.
8. Garcia-Encina G, Farran R, Puig S, Serafini MT, Martinez L. Automated high-performance liquid chromatographic assay for lesopitron, a novel anxiolytic in human plasma using on-line solid-phase extraction. J Chromatogr B Biomed Appl 1995;679:103-10.
9. Physicians' Desk Reference®. Montvale, New Jersey: Medical Economics Data Production Company, 1995.
10. 1A autoreceptors. Behav Pharmacol 1992;3[suppl 1]:19.
11. Gammans RE, Mayol RF, Labudde JA. Metabolism and disposition of buspirone. Am J Med 1986;80:41-51.
12. O'Quigley J, Chevret S. Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Stat Med 1991;10:1647-64.
13. Okuma T. Differential sensitivity to the effects of psychotropic drugs: psychotics vs normals; Asian vs Western populations. Folia Psychiatr Neurol Jpn 1981;35:79-87.
14. Miller AL, Maas JW, Contreras S, Seleshi E, True JE, Bowden C, Castiglioni J. Acute effects of neuroleptics on unmedicated schizophrenic patients and controls. Biol Psychiatry 1993;34:178-87.
15. Owen F, Cross AF, Crow TJ, Longden A, Poulter M, Riley GJ. Increased dopamine receptor sensitivity in schizophrenia. Lancet 1978;2:223-6.
16. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9.
17. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993;8:315-36.
18. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia: a postmortem study. Arch Gen Psychiatry 1993;50:810-8.
19. Sramek JJ, Simpson GM. Pharmacodynamics of antipsychotic drugs in schizophrenia. In: Cutler NR, Sramek JJ, Narang, PK, eds. Pharmacodynamics and drug development: perspectives in clinical pharmacology. Chichester, England: John Wiley, 1994:181-99.
20. Grof P, Akhter MI, Campbell M. Clinical evaluation of psychotropic drugs for psychiatric disorders. Principles and proposed guidelines. Seattle, Washington: Hogrefe & Huber, 1993.
21. Wu JC, Buchsbaum MS, Hershey TG, Hazlett E, Sicotte N, Johnson TC. PET in generalized anxiety disorder. Biol Psychiatry 1991;29:1181-99.
22. Puri SK, Hsu RS, Ho I, Lassman HB. Single dose safety, tolerance and pharmacokinetics of HP 029 in healthy elderly men: a potential Alzheimer's agent. Curr Ther Res 1988;44:766-80.
23. Puri SK, Ho I, Lassman HB. Multiple-dose pharmacokinetics, safety and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease. J Clin Pharmacol 1990;30:948-55.
24. Cutler NR, Murphy MF, Nash RJ, Prior PL, DeLuna DM. Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate(HP 029) in Alzheimer's disease: preliminary findings. J Clin Pharmacol 1990; 30:556-61.
25. Reece PA, Bockbrader H, Sedman AJ. Safety, pharmacodynamics, and pharmacokinetics of a new muscarinic agonist, CI-979 [abstract]. Clin Exp Pharmacol Physiol [Suppl] 1992;21:58.
26. Sramek JJ, Sedman AF, Reece PA, Underwood B, Seifert RD, Bockbrader H, Cutler NR. Safety and tolerability of CI-979 in patients with Alzheimer's disease. Life Sci 1995;57:503-10.
27. Sramek JJ, Hurley DJ, Wardle TS, Satterwhite JH, Hourani J, Dies F, Cutler NR. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol 1995;35:800-6.
28. Goldberg MR, Barchowsky A, McCrea J. Heptylphysostigmine (L-693,487): safety and cholinesterase inhibition in a placebo-controlled rising-dose healthy volunteer study. Presented at the Second International Springfield Symposium on Advances in Alzheimer Therapy, Springfield, Illinois, May 1991.
29. Sramek JJ, Block GA, Reines SA, Sawin SF, Barchowsky A, Cutler NR. A multiple-dose safety trial of eptastigmine in Alzheimer's disease with pharmacodynamic observations of red blood cell cholinesterase. Life Sci 1994;56:319-26.
30. Tollefson GD, Bodick NC, Shannon HC. Xanomeline: a potent and specific M1 agonist in the treatment of Alzheimer's disease. Presented at the annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 12-16, 1994.
31. Psychopharmacologic Drugs Advisory Committee. Meeting on buspirone, Bethesda, Maryland, September 1983.